Adverse health effects of anabolic-androgenic steroids

Regulatory Toxicology and Pharmacology

Volumn 57, Issue 1, 2010, Pages 117-123

  van Amsterdam, Jan ^a   Opperhuizen, Antoon ^a   Hartgens, Fred ^b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aggression; Anabolic steroids; Hepatotoxicity; Illicit drugs; Risk assessment

Indexed keywords

ANABOLIC AGENT; PLACEBO; STANOZOLOL; STEROID; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE ESTER;

ACNE; ACUTE CONFUSION; ACUTE PSYCHOSIS; ADVERSE OUTCOME; AGGRESSIVENESS; ALCOHOL CONSUMPTION; ANXIETY DISORDER; ARTICLE; ATHEROSCLEROSIS; BEHAVIOR DISORDER; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BODY FAT; BREAST DISEASE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONDUCT DISORDER; CRIMINAL BEHAVIOR; DECISION MAKING; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG ABUSE; DRUG DEPENDENCE; DRUG MEGADOSE; DRUG SELF ADMINISTRATION; DRUG USE; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPHONIA; EJACULATION DISORDER; EUPHORIA; FLUID RETENTION; GASTROINTESTINAL IRRITATION; GRANDIOSE DELUSION; GYNECOLOGIC DISEASE; GYNECOMASTIA; HAIR GROWTH; HAIR LOSS; HEADACHE; HEART DEATH; HEART FUNCTION; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HIGH RISK BEHAVIOR; HOSTILITY; HUMAN; HYPERACTIVITY; HYPERTENSION; HYPOMANIA; IMPOTENCE; INJECTION SITE ABSCESS; INJECTION SITE INFECTION; INJECTION SITE PAIN; IRRITABILITY; JAUNDICE; JEALOUS DELUSION; LIVER TOXICITY; MANIA; MASCULINITY; MASTALGIA; MENSTRUATION DISORDER; MENTAL DISEASE; MOOD DISORDER; MUSCLE MALFORMATION; NONHUMAN; OBSESSION; OILY SKIN; PERSONALITY DISORDER; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; SELF ESTEEM; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; STEREOTYPY; STOMACH PAIN; STRIA; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; TESTIS ATROPHY; TIC; VIOLENCE; WITHDRAWAL SYNDROME;

ANABOLIC AGENTS; DOPING IN SPORTS; FEMALE; HUMANS; MALE; SUBSTANCE-RELATED DISORDERS; TESTOSTERONE CONGENERS;

EID: 77951977904     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2010.02.001     Document Type: Article

References (101)

1. Abraham M.D., Kaal H.L., Cohen P.D.A. Licit and Illicit Drug Use in The Netherlands 2001, CEDRO/Mets en Schilt, Amsterdam.
2. Ahlson, H., Ström, R. 2005. Muscle dysmorphia: a quantitative study of gym in Stockholm respective gym in Lidköping. Student Thesis. Available from: (accessed 31.12.09). http://urn.kb.se/resolve?urn=urn:nbn:se:gih:diva-103.
3. Anderson R.A., Bancroft J., Wu F.C. The effects of exogenous testosterone on sexuality and mood of normal men. J. Clin. Endocrinol. Metab. 1992, 75:1503-1507.
4. Anderson R.A., Martin C.W., Kung A.W., Everington D., Pun T.C., Tan K.C., Bancroft J., Sundaram K., Moo-Young A.J., Baird D.T. 7alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. J. Clin. Endocrinol. Metab. 1999, 84:3556-3562.
5. Arnedo M.T., Salvador A., Martinez-Sanchis S., Gonzalez-Bono E. Rewarding properties of testosterone in intact male mice: a pilot study. Pharmacol. Biochem. Behav. 2000, 65:327-332.
6. Bagatell C.J., Bremner W.J. Androgens in men - uses and abuses. N. Engl. J. Med. 1996, 334:707-714.
7. Bagatell C.J., Heiman J.R., Matsumoto A.M., Rivier J.E., Bremner W.J. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J. Clin. Endocrinol. Metab. 1994, 79:561-567.
8. Bahrke M.S., Yesalis C.E., Kopstein A.N., Stephens J.A. Risk factors associated with anabolic-androgenic steroid use among adolescents. Sports Med. 2000, 29:397-405.
9. Basaria S., Wahlstrom J.T., Dobs A.S. Clinical review 138: anabolic-androgenic steroid therapy in the treatment of chronic diseases. J. Clin. Endocrinol. Metab. 2001, 86:5108-5117.
10. Bhasin S., Storer T.W., Berman N., Callegari C., Clevenger B., Phillips J., Bunnell T.J., Tricker R., Shirazi A., Casaburi R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N. Engl. J. Med. 1996, 335:1-7.
11. BMA, 2002. Drugs is sport: the pressure to perform. British Medical Association Board of Science and Education.
12. Brower K.J. Anabolic steroid abuse and dependence. Curr. Psychiatry Rep. 2002, 4:377-387.
13. Brower K.J. Anabolic steroid abuse and dependence in clinical practice. Physician Sport Med. 2009, 37:1-11.
14. Brower K.J., Eliopulos G.A., Blow F.C., Catlin D.H., Beresford T.P. Evidence for physical and psychological dependence on anabolic-androgenic steroids in eight weight lifters. Am. J. Psychiatry 1990, 147:510-512.
15. Brower K.J., Blow F.C., Young J.P., Hill E.M. Symptoms and correlates of anabolic-androgenic steroid dependence. Br. J. Addict. 1991, 86:759-768.
16. Buckley W.E., Yesalis C.E., Friedl K.E., Anderson W.A., Streit A.L., Wright J.E. Estimated prevalence of anabolic steroid use among male high school seniors. JAMA 1988, 260:3441-3445.
17. Choi P.Y., Pope H.-G.J. Violence toward women and illicit androgenic-anabolic steroid use. Ann. Clin. Psychiatry 1994, 6:21-25.
18. Clark A.S., Henderson L.P. Behavioral and physiological responses to anabolic-androgenic steroids. Neurosci. Biobehav. Rev. 2003, 27:413-436.
19. Cohen J., Collins R., Darkes J., Gwartney D. A league of their own: demographics, motivations and patterns of use of 1,955 male adult non-medial anabolic steroid users in the United States. J. Intern. Soc. Sports Nutr. 2007, 4:12-28.
20. Creagh T.M., Rubin A., Evans D.J. Hepatic tumours induced by anabolic steroids in an athlete. J. Clin. Pathol. 1988, 41:441-443.
21. D'Andrea A., Caso P., Salerno G., Scarafile R., De Corato G., Mita C., Di Salvo G., Severino S., Cuomo S., Liccardo B., Esposito N., Calabro R. Left ventricular early myocardial dysfunction after chronic misuse of anabolic-androgenic steroids: a Doppler myocardial and strain imaging analysis. Br. J. Sports Med. 2007, 41:149-155.
22. de Hon O., van Kleij R. Kwaliteit van dopinggeduide middelen 2005, NeCeDo, Capelle aan de IJssel.
23. Detmar S.B., Wiefferink C.H., Vogels T., Paulussen T.G.W.M. Sporters en sportschoolhouders over het gebruik van prestatieverhogende middelen in de sportschool 2003, TNO Preventie en Gezondheid /NeCeDo, Capelle aan de IJssel.
24. DuRant R.H., Escobedo L.G., Heath G.W. Anabolic-steroid use, strength training, and multiple drug use among adolescents in the United States. Pediatrics 1995, 96:23-28.
25. Eklof A.C., Thurelius A.M., Garle M., Rane A., Sjoqvist F. The anti-doping hot-line, a means to capture the abuse of doping agents in the Swedish society and a new service function in clinical pharmacology. Eur. J. Clin. Pharmacol. 2003, 59:571-577.
26. Evans N.A. Current concepts in anabolic-androgenic steroids. Am. J. Sports Med. 2004, 32:534-542.
27. Ferenchick G., Schwartz D., Ball M., Schwartz K. Androgenic-anabolic steroid abuse and platelet aggregation: a pilot study in weight lifters. Am. J. Med. Sci. 1992, 303:78-82.
28. Fineschi V., Riezzo I., Centini F., Silingardi E., Licata M., Beduschi G., Karch S.B. Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. Int. J. Leg. Med. 2007, 121:48-53.
29. Forbes G.B. The effect of anabolic steroids on lean body mass: the dose response curve. Metabolism 1985, 34:571-573.
30. Frankle M.A., Eichberg R., Zachariah S.B. Anabolic-androgenic steroids and a stroke in an athlete: case report. Arch. Phys. Med. Rehabil. 1988, 69:632-633.
31. Freinhar J.P., Alvarez W. Androgen-induced hypomania. J. Clin. Psychiatry 1985, 46:354-355.
32. Hall R.C., Hall R.C. Abuse of supraphysiologic doses of anabolic steroids. South Med. J. 2005, 98:550-555.
33. Hall R.C., Popkin M.K., Stickney S.K., Gardner E.R. Presentation of the steroid psychoses. J. Nerv. Ment. Dis. 1979, 167:229-236.
34. Hartgens F., Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004, 34:513-554.
35. Hartgens F., Rietjens G., Keizer H., Wolffenbuttel B. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br. J. Sports Med. 2004, 38:253-259.
36. Herbst K.L., Bhasin S. Testosterone action on skeletal muscle. Curr. Opin. Clin. Nutr. Metab. Care 2004, 7:271-277.
37. Hurley B.F., Seals D.R., Hagberg J.M., Goldberg A.C., Ostrove S.M., Holloszy J.O., Wiest W.G., Goldberg A.P. High-density-lipoprotein cholesterol in bodybuilders v powerlifters. Negative effects of androgen use. JAMA 1984, 252:507-513.
38. Ishak K.G., Zimmerman H.J. Hepatotoxic effects of the anabolic/androgenic steroids. Semin. Liver Dis. 1987, 7:230-236.
39. Johnson, L.D., O'Malley, P.M., Bachman, J.G., Schulenberg, J.E., 2008. Various stimulant drugs show continuing gradual declines among teens in 2008, most illicit drugs hold steady. University of Michigan News Service, Ann Arbor, MI. Available from: (accessed 31.12.09). http://www.monitoringthefuture.org.
40. Kanayama G., Pope H.G., Cohane G., Hudson J.I. Risk factors for anabolic-androgenic steroid use among weightlifters: a case-control study. Drug Alcohol Depend. 2003, 71:77-86.
41. Kanayama G., Boynes M., Hudson J.I., Field A.E., Pope H.-G.J. Anabolic steroid abuse among teenage girls: an illusory problem?. Drug Alcohol Depend. 2007, 88:156-162.
42. Kanayama G., Hudson J.I., Pope H.-G.J. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern?. Drug Alcohol Depend. 2008, 98:1-12.
43. Kanayama G., Brower K.J., Wood R.I., Hudson J.I., Pope H.-G.J. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction 2009, 104:1966-1978.
44. Karila T.A., Karjalainen J.E., Mantysaari M.J., Viitasalo M.T., Seppala T.A. Anabolic-androgenic steroids produce dose-dependant increase in left ventricular mass in power athletes, and this effect is potentiated by concomitant use of growth hormone. Int. J. Sports Med. 2003, 24:337-343.
45. Kashkin K.B., Kleber H.D. Hooked on hormones? An anabolic steroid addiction hypothesis. JAMA 1989, 262:3166-3170.
46. Kennedy M.C., Lawrence C. Anabolic steroid abuse and cardiac death. Med. J. Aust. 1993, 158:346-348.
47. Kicman A.T. Pharmacology of anabolic steroids. Br. J. Pharmacol. 2008, 154:502-521.
48. Király C.L., Collan Y., Alén M. Effect of testosterone and anabolic steroids on the size of sebaceous glands in power athletes. Am. J. Dermatopathol. 1987, 9:515-519.
49. Koert A.W.A., van Kleij R. Handel in Doping; een verkennend onderzoek naar de handel in dopinggeduide middelen in Nederland 1988, Arko Uitgeverij, Nieuwegein.
50. Krieg A., Scharhag J., Albers T., Kindermann W., Urhausen A. Cardiac tissue Doppler in steroid users. Int. J. Sports Med. 2007, 28:638-643.
51. McCabe S.E., Brower K.J., West B., Nelson T.F., Wechsel H. Trends in non-medical use of anabolic steroids by U.S. college students: results from four national surveys. Drug Alcohol Depend. 2007, 90:243-251.
52. McNutt R.A., Ferenchick G.S., Kirlin P.C., Hamlin N.J. Acute myocardial infarction in a 22-year-old world class weight lifter using anabolic steroids. Am. J. Cardiol. 1988, 62:164.
53. Melchert R.B., Welder A.A. Cardiovascular effects of androgenic-anabolic steroids. Med. Sci. Sports Exerc. 1995, 27:1252-1262.
54. Modlinski R., Fields K.B. The effect of anabolic steroids on the gastrointestinal system, kidneys, and adrenal glands. Curr. Sports Med. Rep. 2006, 5:104-109.
55. NIDA, 2000. NIDA Community Alert Bulletin on Steroid Abuse. Available from: http://www.drugabuse.gov/steroidalert/steroidalert.html.
56. NIDA, 2006. National Institute on Drug Abuse. Research Report Series. Anabolic Steroid Abuse. Why do people abuse anabolic steroids? Available from: http://www.drugabuse.gov/ResearchReports/Steroids/AnabolicSteroids3.html.
57. Nilsson S. Androgenic-anabolic steroid use among male adolescents in Falkenberg. Eur. J. Clin. Pharmacol. 1995, 48:9-11.
58. Nilsson S., Baigi A., Marklund B., Fridlund B. The prevalence of the use of androgenic-anabolic steroids by adolescents in a county of Sweden. Eur. J. Public Health 2001, 11:195-197.
59. Nottin S., Nguyen L.D., Terbah M., Obert P. Cardiovascular effects of androgenic-anabolic steroids in male bodybuilders determined by tissue Doppler imaging. Am. J. Cardiol. 2006, 97:912-915.
60. Nutt D., King L.A., Saulsbury W., Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007, 369:1047-1053.
61. O'Connor D.B., Archer J., Wu F.C. Effects of testosterone on mood, aggression, and sexual behavior in young men: a double-blind, placebo-controlled, cross-over study. J. Clin. Endocrinol. Metab. 2004, 89:2837-2845.
62. Oldersma F., Snippe J., Bieleman B. Doping en handel; onderzoek naar aard en omvang van dopinghandel en ontwikkeling van indicatoren 2002, Intraval Groningen, The Netherlands.
63. Parssinen M., Kujala U., Vartiainen E., Sarna S., Seppala T. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int. J. Sports Med. 2000, 21:225-227.
64. Perry P.J., Yates W.R., Andersen K.H. Psychiatric symptoms associated with anabolic steroids: a controlled, retrospective study. Ann. Clin. Psychiatry 1990, 2:11-17.
65. Perry P.J., Kutscher E.C., Lund B.C., Yates W.R., Holman T.L., Demers L. Measures of aggression and mood changes in male weightlifters with and without androgenic-anabolic steroid use. J. Forensic Sci. 2003, 48:646-651.
66. Petersson A., Garle M., Holmgren P., Druid H., Krantz P., Thiblin I. Toxicological findings and manner of death in autopsied users of anabolic-androgenic steroids. Drug Alcohol Depend. 2006, 81:241-249.
67. Pope H.-G.J., Katz D.L. Affective and psychotic symptoms associated with anabolic steroid use. Am. J. Psychiatry 1988, 145:487-490.
68. Pope H.-G.J., Katz D.L. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch. Gen. Psychiatry 1994, 51:375-382.
69. Pope H.-G.J., Gruber A.J., Choi P.Y., Olivardia R., Phillips K.A. Muscle dysmorphia. An underrecognized form of body dysmorphic disorder. Psychosomatics 1997, 38:548-557.
70. Pope H.-G.J., Gruber A.J., Mangweth B., Bureau B., deCol C., Jouvent R., Hudson J.I. Body image perception among men in three countries. Am. J. Psychiatry 2000, 157:1297-1301.
71. Pope H.-G.J., Kouri E.M., Hudson J.I. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch. Gen. Psychiatry 2000, 57:133-140.
72. Rashid H., Osmerod S., Day E. Anabolic-androgenic steroids: what the psychiatrist needs to know. Adv. Psychiatry Treat. 2007, 13:203-211.
73. Rogol A.D., Yesalis C.E. Clinical review 31: anabolic-androgenic steroids and athletes: what are the issues?. J. Clin. Endocrinol. Metab. 1992, 74:465-469.
74. Salas-Ramirez K.Y., Montalto P.R., Sisk C.L. Anabolic-androgenic steroids differentially affect social behaviors in adolescent and adult male Syrian hamsters. Horm. Behav. 2008, 53:378-385.
75. Scally M.C., Tan R.S. Complexities in clarifying the diagnostic criteria for anabolic-androgenic steroid dependence. Am. J. Psychiatry 2009, 166:1187.
76. Shifren J.L. The role of androgens in female sexual dysfunction. Mayo Clin. Proc. 2004, 79:S19-S24.
77. Silva P.R., Machado L.-C.J., Figueiredo V.C., Cioffi A.P., Prestes M.C., Czepielewski M.A. Prevalencia do uso de agentes anabolicos em praticantes de musculacao de Porto Alegre. [Prevalence of the use of anabolic agents among strength training apprentices in Porto Alegre, RS]. Arq. Bras. Endocrinol. Metabol. 2007, 51:104-110.
78. Singh A.B., Hsia S., Alaupovic P., Sinha-Hikim I., Woodhouse L., Buchanan T.A., Shen R., Bross R., Berman N., Bhasin S. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J. Clin. Endocrinol. Metab. 2002, 87:136-143.
79. Sinha-Hikim I., Artaza J., Woodhouse L., Gonzalez-Cadavid N., Singh A.B., Lee M.I., Storer T.W., Casaburi R., Shen R., Bhasin S. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am. J. Physiol. Endocrinol. Metab. 2002, 283:E154-E164.
80. Sjoqvist F., Garle M., Rane A. Use of doping agents, particularly anabolic steroids, in sports and society. Lancet 2008, 371:1872-1882.
81. Soe K.L., Soe M., Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver 1992, 12:73-79.
82. Stimac D., Milic S., Dintinjana R.D., Kovac D., Ristic S. Androgenic/anabolic steroid-induced toxic hepatitis. J. Clin. Gastroenterol. 2002, 35:350-352.
83. Stubbe, J.H., Chorus, A.M.J., Frank, L.E., de Hon, O., Schermers, P., vander Heiden, P.G.M., 2009. Prestatiebevorderende middelen bij fitnessbeoefenaars. Dopingautoriteit.
84. Sullivan M.L., Martinez C.M., Gennis P., Gallagher E.J. The cardiac toxicity of anabolic steroids. Prog. Cardiovasc. Dis. 1998, 41:1-15.
85. Surmann A., Baberowski H.P., Müller-Platz C. Dopingbekämpfung in kommerziell geführten Fitnessstudios 2002, Niedersächsisches Innenministerium, Hannover.
86. Tan R.S., Scally M.C. Anabolic steroid-induced hypogonadism. Towards a unified hypothesis of anabolic steroid action. Med. Hypotheses 2009, 72:723-728.
87. Thiblin I., Petersson A. Pharmacoepidemiology of anabolic-androgenic steroids: a review. Fundam. Clin. Pharmacol. 2005, 19:27-44.
88. Thiblin I., Kristiansson M., Rajs J. Anabolic-androgenic steroids and behavioural patterns among violent offenders. J. Forensic Psychiatry 1997, 8:299-310.
89. Thiblin I., Lindquist O., Rajs J. Cause and manner of death among users of anabolic-androgenic steroids. J. Forensic Sci. 2000, 45:16-23.
90. Thompson P.D., Cullinane E.M., Sady S.P., Chenevert C., Saritelli A.L., Sady M.A., Herbert P.N. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989, 261:1165-1168.
91. Togna G.I., Togna A.R., Graziani M., Franconi M. Testosterone and cocaine: vascular toxicity of their concomitant abuse. Thromb. Res. 2003, 109:195-201.
92. van den Heuvel M., van Kalmthout J., van den Houdt F. Doping in de Breedtesport. Een onderzoek naar de aard en omvang van het gebruik van dopinggeduide middelen in de georganiseerde breedtesport 2002, NeCeDo/W.J.H. Mulier Instituut, Amsterdam.
93. Vogel R.A. Alcohol, heart disease, and mortality: a review. Rev. Cardiovasc. Med. 2002, 3:7-13.
94. Wang C., Swerdloff R.S., Iranmanesh A., Dobs A., Snyder P.J., Cunningham G., Matsumoto A.M., Weber T., Berman N. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J. Clin. Endocrinol. Metab. 2000, 85:2839-2853.
95. Welder A.A., Robertson J.W., Melchert R.B. Toxic effects of anabolic-androgenic steroids in primary rat hepatic cell cultures. J. Pharmacol. Toxicol. Methods 1995, 33:187-195.
96. Williamson D.J. Anabolic steroid use among students at a British college of technology. Br. J. Sports Med. 1993, 27:200-201.
97. Wilson J.D. Androgen abuse by athletes. Endocr. Rev. 1988, 9:181-199.
98. Wilson J.D. Androgens. Goodman and Gilman's the Pharmacological Basis of Therapeutics 1992, vol. 8:1413-1462. McGraw-Hill Inc.
99. Wood R.I. Reinforcing aspects of androgens. Physiol. Behav. 2004, 83:279-289.
100. Yesalis C.E., Barsukiewicz C.K., Kopstein A.N., Bahrke M.S. Trends in anabolic-androgenic steroid use among adolescents. Arch. Pediatr. Adolesc. Med. 1997, 151:1197-1206.
101. Young N.R., Baker H.W., Liu G., Seeman E. Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception. J. Clin. Endocrinol. Metab. 1993, 77:1028-1032.